Related Experiment Video
Updated: Dec 7, 2025
Author Spotlight: Advancing Treatment Approaches with Adipose-Derived Stem Cells
Published on: January 12, 2024
Mesenchymal stem cell research progress for the treatment of COVID-19
Dezhi Yao1, Huanrong Ye1, Zhirong Huo1
1Department of Respiratory, Songshan Lake Central Hospital, Dongguan, Guangdong Province, China.
Insights
Mesenchymal stem cells (MSCs) show promise for treating severe COVID-19 by reducing complications and mortality. Clinical trials are underway in China to evaluate MSCs
Area of Science:
- Regenerative Medicine
- Infectious Diseases
- Immunology
Background:
- COVID-19, a novel coronavirus infection, emerged in late 2019 with significant global health implications.
- Severe COVID-19 cases can rapidly progress to critical conditions including ARDS, sepsis, and multi-organ failure.
- Current treatments for severe COVID-19 lack efficacy, highlighting the need for novel therapeutic approaches.
Purpose of the Study:
- To review the current research progress on utilizing mesenchymal stem cells (MSCs) for treating COVID-19 patients.
- To explore the potential of MSCs in mitigating severe COVID-19 complications and improving patient outcomes.
Main Methods:
- Review of existing scientific literature and ongoing clinical trials.
- Analysis of MSCs' therapeutic properties, including anti-inflammatory and immunomodulatory effects.
- Examination of MSCs' potential to improve the microenvironment, promote neovascularization, and enhance tissue repair.
Main Results:
- Mesenchymal stem cells (MSCs) possess potent anti-inflammatory and immunomodulatory capabilities.
- MSCs can potentially improve the local tissue microenvironment, stimulate new blood vessel formation, and aid in tissue repair.
- Several clinical trials in China are actively investigating the efficacy of MSCs in treating COVID-19.
Conclusions:
- Mesenchymal stem cells (MSCs) offer a promising therapeutic strategy for severe COVID-19.
- The immunomodulatory and regenerative properties of MSCs may reduce the risk of complications and mortality.
- Further clinical research is essential to validate the effectiveness of MSC-based therapies for COVID-19.
Abstract:
At the end of 2019, novel coronavirus (COVID-19) infection was detected in Wuhan City, Hubei Province, China. The COVID-19 infection characteristics include a long incubation period, strong infectivity, and high fatality rate, and it negatively affects human health and social development. COVID-19 has become a common problem in the global medical and health system. It is essentially an acute self-limiting disease. Patients with severe COVID-19 infection usually progress to acute respiratory distress syndrome, sepsis, metabolic acidosis that is difficult to correct, coagulation dysfunction, multiple organ failure, and even death within a short period after onset. There remains a lack of effective drugs for such patients clinically. Mesenchymal stem cells (MSCs) are expected to reduce the risk of complications and death in patients because they have strong anti-inflammatory and immunomodulatory capabilities, which can improve the microenvironment, promote neovascularization, and enhance tissue repair capabilities. China is currently conducting several clinical trials on MSCs for the treatment of COVID-19. Here, we review the research progress related to using stem cells to treat patients with COVID-19.
More Related Videos
04:09Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
Published on: March 3, 2023
09:03Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow
Published on: March 17, 2023
Related Concept Videos
01:19Mesenchymal Stem Cells
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:22iPS Cell Differentiation
01:17Stem Cell Culture